Physicochemical characterization of siRNA-peptide complexes.
Short interfering RNAs (siRNAs) trigger RNA interference (RNAi), where the complementary mRNA is degraded, resulting in silencing of the encoded protein. A delivery carrier is desired to increase the solution stability of siRNA and improve its cellular uptake to overcome its rapid enzymatic degradation and low transfection efficiency. In this study, Arginine-9 (R9), a cell-penetrating peptide derived from the HIV 1 Tat protein, was investigated as a potential carrier for siRNAs. A connective tissue growth factor (CTGF) encoding siRNA was used because of its therapeutic potential of treating breast cancer. The interaction between R9 and siRNA was studied by UV/vis spectroscopy and circular dichroism (CD). The hydrodynamic diameter of the siRNA-R9 complexes was determined by dynamic light scattering (DLS), and the Zeta potential of the complexes was obtained by measuring the electrophoretic mobility. The effect of salt addition is also quantified using UV-vis spectroscopy. The siRNA and R9 readily formed complexes/aggregates through molecular association, accompanying a change in surface charge with increasing peptide concentration, reaching a maximum hydrodynamic diameter of approximately 1 mum at siRNA saturation. The highest binding ratio of R9 to siRNA determined from the UV/vis spectra and CD is 10.3:1 and 39.1:1 from DLS (corresponds to charge ratios of 2.2:1 (+/-) and 8.4:1, respectively). The difference in binding ratio is possibly because of the difference in signal contribution between absorption and light scattering. The physicochemical characterization of CTGF siRNA-R9 complexes presented here have shown that various methods can be used to control the properties of the siRNA-peptide complexes, which provide a basis for the formulation of siRNA therapeutics with peptide carriers.
Law
Maggie
M
Dept. of Chemical Engineering, University of Waterloo, Waterloo, ON, Canada N2L 3G1.
Jafari
Mousa
M
Chen
P
P
D002626:Chemistry, Pharmaceutical / Q000379:methods*; D002942:Circular Dichroism; D055513:Connective Tissue Growth Factor / Q000235:genetics; D004337:Drug Carriers / Q000737:chemistry*; D006801:Humans; D010455:Peptides / Q000737:chemistry*; D034741:RNA, Small Interfering / Q000737:chemistry* / Q000235:genetics
D004337:Drug Carriers; D010455:Peptides; D034741:RNA, Small Interfering; D055513:Connective Tissue Growth Factor